Robert Nelsen
Co-Founder & Managing Director @ ARCH Venture Partners
New York, United States
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN);Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL, Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation.Mr. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
- Total investments:
- 96
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Robert Nelsen invests in
Stages Robert Nelsen invests in
Countries Robert Nelsen invests in
Round sizes
Round size
- Series A
- $15M–$216M
- Series B
- $25M–$200M
- Series C
- $31M–$205M
Investment Focus
Industry
- Biotechnology 35 (36%)
- Health Care 26 (27%)
- Therapeutics 12 (13%)
- Pharmaceutical 11 (11%)
- Medical 9 (9%)
Stage
- Series B 30 (31%)
- Series A 29 (30%)
- Series C 12 (13%)
- Seed 5 (5%)
- Series D 3 (3%)
Country
- United States 46 (48%)
- China 2 (2%)
- Israel 1 (1%)
- United Kingdom 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
LifeMine Therapeutics
|
Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $188M / Series E / Aug 06, 2026 | |
Trase
|
Trase provides and implements complete AI agent solutions, allowing businesses to automate complicated administrative procedures and operations in a safe and secure manner. | $107M / Seed / Jun 24, 2026 | |
City Therapeutics
|
City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M / Series B / Jun 08, 2026 | |
Paradigm
|
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. | $78M / Series B / Dec 04, 2025 | |
SciNeuro
|
SciNeuro is a biotechnology company focused on developing innovative medicines for patients with central nervous system diseases. | $53M / Venture - Series Unknown / Dec 04, 2025 | |
Dispatch Bio
|
Dispatch Bio helps create a world where all cancer patients can be cured. | $216M / Series A / Jul 23, 2025 | |
Be Biopharma
|
Be Biopharma is developing B cells as medicines. | $92M / Series C / Jan 15, 2025 | |
|
Be Biopharma
|
Be Biopharma is developing B cells as medicines. | $82M / Venture - Series Unknown / Oct 22, 2024 | |
|
City Therapeutics
|
City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $135M / Series A / Oct 08, 2024 | |
Stability AI
|
Stability AI is an artificial intelligence-driven visual art startup that designs and implements open AI tools. The company focuses on creating open models for various media types, including image, video, 3D, and audio, with applications also targeting enterprise-level needs. Stability AI fosters a vibrant community involving experts and partnersworldwide, enhancing collaboration in developing AI tools. | $80M / Venture - Series Unknown / Jun 25, 2024 | |
| See all 96 investments → | |||
Co-Investors
Google Ventures
22 deals together
Venrock
19 deals together
F-Prime
14 deals together
Lux Capital
9 deals together
Third Rock Ventures
9 deals together
Bezos Expeditions
8 deals together
About ARCH Venture Partners
ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories.ARCH has raised ten venture fundstotaling over $3 billion and has invested in the venture capital rounds for more than 150 companies. ARCH investors include corporations, pension funds, endowment funds, financial institutions, and private investors.
ARCH Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cindy Bayley
Affiliate
|
|||
Clinton Bybee
Co-Founder and Managing Director
|
|||
Hong Hou
Venture Partner
|
|||
Keith Crandell
Co-founder & Managing Director
|
|||
Kristina Burow
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Robert Nelsen invest in?
Robert Nelsen invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 96 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Robert Nelsen's check size?
Robert Nelsen typically joins rounds of $15M–$216M at Series A, $25M–$200M at Series B and $31M–$205M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Robert Nelsen participates in.
When did Robert Nelsen last invest?
The most recent investment recorded for Robert Nelsen closed in Aug 2026. Shizune tracks 96 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
